三氧化二砷血药浓度监测中国专家共识OA

Arsenic trioxide(ATO)is not only a first-line therapy for acute promyelocytic leukemia(APL)but also a widely accepted treatment in other malignancies.However,ATO therapy may lead to suboptimal efficacy or toxic reactions due to its complex active metabolites and significant in-terindividual pharmacokinetic variability.Blood con-centration monitoring,which employs various ana-lytical techniques to determine drug exposure lev-els in vivo,serves as both a fundamental technical approach and a core component of personalized medication.This expert consensus systematically discusses the target population for ATO blood drug monitoring,monitoring indicators,optimal sam-pling times,monitoring recommendations for spe-cial populations,and methodological approaches based on current evidence.The primary objectives are to standardize clinical implementation of blood concentration monitoring in ATO treatment and to advance precision medicine practice.